Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study

NCT04134559 is registered in ClinicalTrials.gov with Allison O'Neill, MD as lead sponsor.

NCT NCT04134559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04134559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study
Lead sponsor
Allison O'Neill, MD
Phase
Phase 2
Overall status
Recruiting
Start date
November 1, 2020
Completion date
January 1, 2028
Enrollment
18 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fibrolamellar carcinoma, hepatocellular carcinoma, childhood, liver cancer, liver cancer, pediatric